TUB4 Antibody

What is TUBB4A and why is it an important research target?

TUBB4A (tubulin beta 4A class IVa) is a specialized isoform of beta-tubulin that forms heterodimers with alpha-tubulin to create microtubules, which are essential cytoskeletal structures. Microtubules are involved in maintaining cell shape, intracellular transport, and cell division. TUBB4A is particularly enriched in neuronal tissues and has been implicated in several neurological disorders, including dystonia type 4 (DYT4). The protein plays critical roles in forming dynamic structures within cells, making it an important target for studies investigating cytoskeletal functions and neurological pathologies .

What types of TUBB4A antibodies are available for research applications?

Multiple types of TUBB4A antibodies with varying characteristics are available for research:

These antibodies differ in specificity, sensitivity, and optimal applications, which should be considered when designing experiments .

How does the molecular structure of TUBB4A differ from other tubulin isoforms?

TUBB4A is one of several beta-tubulin isotypes that share high sequence homology but differ in their C-terminal regions. The protein has a predicted molecular weight of approximately 49.4 kDa. TUBB4A contains specific amino acid sequences that distinguish it from other beta-tubulin isoforms, which can affect its post-translational modifications, interactions with microtubule-associated proteins, and incorporation into microtubules. These subtle structural differences contribute to specialized functions in different cell types, particularly in neurons where TUBB4A is prominently expressed .

How should I design proper controls for TUBB4A antibody experiments?

Robust experimental design for TUBB4A antibody research requires multiple controls:

• Positive control: Include samples known to express TUBB4A (e.g., neuronal tissues or cell lines)

• Negative control: Use samples where TUBB4A expression is absent or knocked down

• Isotype control: Include an antibody of the same isotype (e.g., IgG2b for mouse monoclonal OTI5C1) but irrelevant specificity

• Secondary antibody-only control: Apply only the secondary antibody to verify absence of non-specific binding

• Competing peptide control: Pre-incubate the antibody with the immunizing peptide to confirm specificity

The lack of appropriate controls is a major contributor to the reproducibility crisis in antibody-based research, with Johns Hopkins researchers estimating that at least half of published manuscripts contain potentially incorrect immunohistochemical staining results due to insufficient antibody validation .

What factors affect the sensitivity and specificity of TUBB4A antibody detection?

Multiple factors can significantly impact TUBB4A antibody performance:

• Fixation method: Formaldehyde fixation may mask epitopes recognized by certain TUBB4A antibodies

• Antigen retrieval: Different protocols may be required depending on the epitope and sample preparation

• Antibody concentration: Optimal dilutions vary by application (e.g., WB 1:500-2000, IHC 1:150, IF 1:100, FC 1:100)

• Incubation conditions: Temperature, time, and buffer composition affect antibody binding kinetics

• Detection system: Enhanced chemiluminescence vs. fluorescence-based detection systems offer different sensitivity thresholds

• Sample preparation: Denaturation for Western blot vs. native conformation for immunofluorescence

• Cross-reactivity: Some TUBB4A antibodies may cross-react with other tubulin isoforms

Optimization of these parameters is essential for obtaining reliable and reproducible results .

How can I quantitatively measure TUBB4A expression levels?

Quantitative measurement of TUBB4A requires careful standardization:

• Western blot densitometry: Normalize TUBB4A band intensity to loading controls (e.g., GAPDH, actin)

• Quantitative immunofluorescence: Measure fluorescence intensity using appropriate software, with standardized exposure settings

• Flow cytometry: Determine mean fluorescence intensity using properly validated antibodies (e.g., OTI5C1 at 1:100 dilution)

• qPCR: Complement protein-level measurements with mRNA quantification

• Mass spectrometry: For absolute quantification, use isotope-labeled peptide standards

Regardless of method, standard curves with known quantities of recombinant TUBB4A should be included for absolute quantification .

How can I validate the specificity of a commercial TUBB4A antibody?

Comprehensive validation should include multiple approaches:

• Genetic validation: Test antibody in TUBB4A knockout/knockdown models

• Orthogonal validation: Compare results from antibody-based methods with orthogonal techniques (mass spectrometry, RNA-seq)

• Independent antibody validation: Use multiple antibodies targeting different epitopes of TUBB4A

• Cell/tissue expression pattern analysis: Verify that staining patterns match known TUBB4A expression profiles

• Immunoprecipitation followed by mass spectrometry: Confirm the antibody pulls down TUBB4A protein

• Recombinant expression: Test antibody against overexpressed TUBB4A and related isoforms to assess cross-reactivity

The reproducibility crisis in biomedical research has highlighted antibody validation as a critical issue, with estimated $2 billion spent annually on antibodies and a significant fraction wasted on unreliable results .

Why might different TUBB4A antibodies yield conflicting results?

Discrepancies between different TUBB4A antibodies can arise from several factors:

• Epitope differences: Antibodies targeting different regions of TUBB4A may be differentially affected by protein conformation or post-translational modifications

• Antibody class variations: Monoclonal vs. polyclonal antibodies offer different specificity/sensitivity profiles

• Clone-specific characteristics: Different monoclonal clones (e.g., OTI5C1 vs. EPR16775) may have unique binding properties

• Host species differences: Mouse-derived vs. rabbit-derived antibodies may perform differently in certain applications

• Validation stringency: Manufacturers apply varying levels of validation to their antibodies

• Lot-to-lot variability: Production methods may result in inconsistent performance between batches

When conflicting results are obtained, researchers should systematically compare antibodies using standardized conditions and include appropriate controls to identify the most reliable reagent .

What best practices should be followed when reporting TUBB4A antibody experiments?

To enhance reproducibility, researchers should report:

• Complete antibody information: Manufacturer, catalog number, clone, lot number, RRID (Research Resource Identifier)

• Validation evidence: Specific validation steps performed for the particular application

• Detailed methods: Complete protocols including dilutions, incubation times/temperatures, buffers

• Imaging parameters: For microscopy, include exposure settings, gain, objective specifications

• Quantification methods: Detailed description of how measurements were performed

• Controls: Description of all controls used and their results

• Raw data availability: Consider sharing unprocessed images/blots in repositories

Following these reporting guidelines can help address the "reproducibility crisis" affecting antibody-based research, as highlighted by Johns Hopkins researchers who found widespread inconsistencies in immunohistochemical staining protocols across laboratories .

What are the optimal conditions for Western blot detection of TUBB4A?

For optimal Western blot detection of TUBB4A, consider the following methodological details:

• Sample preparation: Lyse cells in RIPA buffer containing protease inhibitors; denature samples at 95°C for 5 minutes in Laemmli buffer

• Gel selection: Use 10-12% polyacrylamide gels to properly resolve the 49.4 kDa TUBB4A protein

• Transfer conditions: Semi-dry transfer at 15V for 60 minutes or wet transfer at 100V for 90 minutes

• Blocking solution: 5% non-fat dry milk in TBST for 1 hour at room temperature

• Primary antibody: Anti-TUBB4A (e.g., clone OTI5C1) at 1:500-2000 dilution, incubated overnight at 4°C

• Secondary antibody: HRP-conjugated appropriate secondary (e.g., goat anti-mouse IgG) at 1:1000-5000 dilution

• Detection: Enhanced chemiluminescence with exposure times optimized for signal-to-noise ratio

When analyzing results, compare band intensity to appropriate loading controls and include molecular weight markers to confirm the expected size of 49.4 kDa .

What considerations are important for immunofluorescence studies using TUBB4A antibodies?

For successful immunofluorescence detection of TUBB4A:

• Fixation method: 4% paraformaldehyde for 10 minutes preserves microtubule structures while allowing antibody accessibility

• Permeabilization: 0.1% Triton X-100 for 5 minutes enables antibody access to cytoplasmic TUBB4A

• Blocking: Use 1% BSA/10% normal serum/0.3M glycine in 0.1% PBS-Tween for 1 hour

• Primary antibody dilution: Use anti-TUBB4A at 1:100 dilution and incubate overnight at 4°C

• Washing steps: Perform 3 x 5-minute washes with PBS between antibody incubations

• Counter-staining: Include DAPI (1:1000) for nuclear visualization

• Mounting medium: Use anti-fade mounting medium to prevent photobleaching

• Controls: Include samples without primary antibody and negative control tissues

The staining pattern should show cytoplasmic filamentous structures consistent with microtubule organization, as demonstrated in SKNSH cells stained with Alexa Fluor 488-conjugated anti-beta IV Tubulin antibody .

How should I troubleshoot weak or non-specific TUBB4A antibody signals?

When facing suboptimal TUBB4A antibody performance, systematically address these issues:

For weak signal:

• Increase antibody concentration (reduce dilution)

• Extend incubation time or increase temperature

• Optimize antigen retrieval (for fixed tissues)

• Try alternative detection systems with higher sensitivity

• Check sample preparation to ensure protein integrity

For non-specific signal:

• Increase blocking time or try alternative blocking reagents

• Test more stringent washing conditions

• Reduce primary and secondary antibody concentrations

• Pre-absorb antibody with negative control lysates

• Try alternative antibody clones targeting different epitopes

For background issues:

• Use freshly prepared buffers to reduce background

• Filter buffers to remove particulates that may cause artifacts

• Ensure complete removal of excess secondary antibody

• Include detergents in washing buffers to reduce non-specific binding

• Consider using monoclonal antibodies which typically have higher specificity than polyclonals .

How can I use TUBB4A antibodies to study neurological disorders?

TUBB4A antibodies enable several approaches to investigate neurological conditions:

• Expression analysis in disease models: Compare TUBB4A protein levels in control vs. disease tissues using Western blot or immunohistochemistry

• Subcellular localization studies: Use immunofluorescence to analyze potential mislocalization of TUBB4A in disease states

• Post-translational modification detection: Combine TUBB4A antibodies with modification-specific antibodies to study disease-associated alterations

• Protein-protein interaction changes: Use TUBB4A antibodies for co-immunoprecipitation to identify altered binding partners in pathological conditions

• Mutation-specific detection: Develop or obtain antibodies that specifically recognize disease-associated TUBB4A mutations

• Therapeutic monitoring: Track TUBB4A expression or localization changes in response to experimental treatments

TUBB4A mutations are associated with DYT4 (dystonia type 4), making these antibodies valuable tools for studying this and related neurological disorders .

What approaches can be used to study post-translational modifications of TUBB4A?

Investigating post-translational modifications (PTMs) of TUBB4A requires specialized techniques:

• PTM-specific antibodies: Use antibodies that recognize specific modifications (phosphorylation, acetylation, etc.) on TUBB4A

• Two-dimensional electrophoresis: Separate TUBB4A isoforms based on both molecular weight and isoelectric point

• Mass spectrometry: Identify specific modification sites after immunoprecipitation with TUBB4A antibodies

• Sequential immunoprecipitation: First immunoprecipitate with TUBB4A antibody, then probe with PTM-specific antibodies

• In vitro modification assays: Treat purified TUBB4A with specific enzymes and detect changes with TUBB4A antibodies

• Pharmacological manipulation: Treat cells with inhibitors of specific modification enzymes and monitor TUBB4A status

Understanding PTMs is crucial as they regulate microtubule dynamics, stability, and interactions with microtubule-associated proteins .

How can TUBB4A antibodies be used in multiplexed imaging applications?

Advanced multiplexed imaging with TUBB4A antibodies requires careful planning:

• Antibody species selection: Choose primary antibodies raised in different host species to avoid cross-reactivity

• Fluorophore selection: Select fluorophores with minimal spectral overlap (e.g., Alexa Fluor 488 for TUBB4A and Alexa Fluor 647 for other targets)

• Sequential staining: For same-species antibodies, use sequential staining with complete elution between rounds

• Cyclic immunofluorescence: Perform multiple rounds of staining, imaging, and fluorophore inactivation

• Spectral unmixing: Use computational approaches to separate overlapping fluorescence signals

• Co-localization analysis: Quantify spatial relationships between TUBB4A and other cellular components

Alexa Fluor 488-conjugated anti-beta IV Tubulin antibody has been successfully used in co-localization studies with the lysosomal marker LAMP1 using super-resolution microscopy, demonstrating the utility of these approaches .

How are TUBB4A antibodies being utilized in antibody-drug conjugate development?

Recent research explores the application of tubulin biology in antibody-drug conjugate (ADC) development:

• Tub-tag technology: This innovative approach uses the enzyme tubulin tyrosine ligase (TTL) to add modified tyrosine residues to specific protein sequences derived from α-tubulin

• Site-specific conjugation: The Tub-tag sequence (VDSVEGEGEEEGEE) provides a hydrophilic microenvironment favorable for conjugating hydrophobic payloads

• Improved stability: ADCs developed using Tub-tag technology show reduced high molecular weight species formation under stress conditions

• Reduced non-specific uptake: The hydrophilic nature of Tub-tag sequences contributes to reduced non-specific cellular uptake and cytotoxicity

• Application examples: TUB-010, an anti-CD30 ADC utilizing Tub-tag technology, demonstrated improved tumor control in xenograft models

While not directly using TUBB4A antibodies, this technology leverages tubulin biology principles for next-generation therapeutic antibody development .

What role might TUBB4A antibodies play in COVID-19 and other infectious disease research?

While primarily used in neuroscience and cancer research, TUBB4A antibodies have potential applications in infectious disease studies:

• Cytoskeletal changes during infection: Monitor TUBB4A dynamics during viral infection, as many viruses manipulate the host cytoskeleton

• Pathway analysis: Study the involvement of TUBB4A in infection-related signaling pathways

• Cross-platform validation: Use TUBB4A as a control in antibody-based studies of viral proteins

• Methodology transfer: Apply antibody validation principles established in TUBB4A research to developing reliable serological tests

• Technical expertise sharing: The NCI's $306 million initiative for serology research recognizes the potential for knowledge transfer between cancer antibody research and infectious disease applications

The COVID-19 pandemic has highlighted connections between immunology, oncology, and infectious disease research, with NCI Director Ned Sharpless noting, "I will be very surprised and very sad if we don't get some new cancer antibody work out of this, because it's just so natural" .

What computational approaches are enhancing TUBB4A antibody design and specificity?

Computational methods are revolutionizing antibody research including TUBB4A applications:

• In silico epitope prediction: Computational tools identify optimal TUBB4A epitopes for antibody generation

• Antibody-antigen docking simulations: Predict binding interactions between antibodies and TUBB4A

• Machine learning for specificity prediction: Train models on experimental data to design antibodies with customized specificity profiles

• Structural biology integration: Incorporate crystallography and cryo-EM data into antibody design processes

• Phage display optimization: Computational analysis of selection experiments to identify optimal binding sequences

• Cross-reactivity prediction: Algorithms that assess potential cross-reactivity with other tubulin isoforms

These computational approaches complement traditional experimental methods and may help address the reproducibility challenges in antibody research by enabling more rational design of highly specific antibodies .